ECSP088403A - Formulacion farmaceutica de absorción oral y su método de administracion - Google Patents

Formulacion farmaceutica de absorción oral y su método de administracion

Info

Publication number
ECSP088403A
ECSP088403A EC2008008403A ECSP088403A ECSP088403A EC SP088403 A ECSP088403 A EC SP088403A EC 2008008403 A EC2008008403 A EC 2008008403A EC SP088403 A ECSP088403 A EC SP088403A EC SP088403 A ECSP088403 A EC SP088403A
Authority
EC
Ecuador
Prior art keywords
micelle
pharmaceutical formulation
aerosol
formulation
administration
Prior art date
Application number
EC2008008403A
Other languages
English (en)
Inventor
Anna E Gluskin
Muhammad Waseem Tahir Qazi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of ECSP088403A publication Critical patent/ECSP088403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una formulación farmacéutica para absorber por la mucosa oral que incluye una cantidad efectiva de (a) un agente farmacéutico en forma de micela combinada, (b) al menos unCompuesto formador de micela seleccionado del grupo de sulfato alquilo de metal alcalino y monooleato de sorbitan polioxietileno, (c) un copolímero bloque de polioxietileno y polioxipropileno, (d) al menos un compuesto formador de micela adicional y (e) un disolvente adecuado. La invención proporciona además un dispensador de dosis graduado (aerosol y no aerosol) que contiene la presente formulación y un método de administración de insulina con un dispensador de dosis graduado que incluye administrar dosis múltiples de una formulación que contiene insulina antes y después de cada comida.
EC2008008403A 2005-11-30 2008-04-25 Formulacion farmaceutica de absorción oral y su método de administracion ECSP088403A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2005/001816 WO2007062494A1 (en) 2005-11-30 2005-11-30 Orally absorbed pharmaceutical formulation and method of administration

Publications (1)

Publication Number Publication Date
ECSP088403A true ECSP088403A (es) 2008-05-30

Family

ID=38091821

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008403A ECSP088403A (es) 2005-11-30 2008-04-25 Formulacion farmaceutica de absorción oral y su método de administracion

Country Status (15)

Country Link
US (2) US20090214657A1 (es)
EP (1) EP1954242A4 (es)
JP (1) JP2009517410A (es)
CN (1) CN101309668A (es)
AP (1) AP2008004447A0 (es)
AR (1) AR057180A1 (es)
AU (1) AU2005338631B2 (es)
BR (1) BRPI0520704A2 (es)
CA (1) CA2630578C (es)
EA (1) EA200800979A1 (es)
EC (1) ECSP088403A (es)
IL (1) IL191531A0 (es)
NZ (1) NZ567601A (es)
UY (1) UY29905A1 (es)
WO (1) WO2007062494A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015456A1 (en) * 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
CN101422431B (zh) * 2007-12-28 2011-03-23 上海医药工业研究院 胰岛素经鼻给药制剂
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
CN100594929C (zh) * 2009-06-24 2010-03-24 薛南荣 口服胰岛素药物及其制备方法
PL2498801T3 (pl) 2009-11-13 2018-08-31 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
MX2012007806A (es) * 2010-01-12 2012-08-01 Novo Nordisk As Composiciones farmaceuticas para administracion oral de peptidos de insulina.
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102228680B (zh) * 2011-06-14 2013-02-27 中国人民解放军第三0二医院 胸腺肽的磷脂/胆盐复合胶束及其制备方法和制剂
EP2723321A4 (en) * 2011-06-27 2015-07-01 Univ Texas RINGING PHARMACEUTICAL FORMULATIONS
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
MY181626A (en) 2013-04-03 2020-12-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AU2016335287A1 (en) 2015-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
ATE198268T1 (de) * 1992-10-08 2001-01-15 Supratek Pharma Inc Zusammensetzung von in mizellen eingeschlossenen antineoplastischen wirkstoffen
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US6063762A (en) * 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6436367B1 (en) * 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6375975B1 (en) * 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
WO2000074736A1 (en) * 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same

Also Published As

Publication number Publication date
JP2009517410A (ja) 2009-04-30
UY29905A1 (es) 2007-05-31
AR057180A1 (es) 2007-11-21
AU2005338631B2 (en) 2011-12-01
EA200800979A1 (ru) 2008-10-30
IL191531A0 (en) 2008-12-29
CA2630578A1 (en) 2007-06-07
BRPI0520704A2 (pt) 2009-05-19
CN101309668A (zh) 2008-11-19
WO2007062494A1 (en) 2007-06-07
AP2008004447A0 (en) 2008-04-30
EP1954242A1 (en) 2008-08-13
EP1954242A4 (en) 2012-08-01
NZ567601A (en) 2010-12-24
AU2005338631A1 (en) 2007-06-07
US20090214657A1 (en) 2009-08-27
US20120171259A1 (en) 2012-07-05
CA2630578C (en) 2014-04-15

Similar Documents

Publication Publication Date Title
ECSP088403A (es) Formulacion farmaceutica de absorción oral y su método de administracion
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
DK1257254T3 (da) Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom
AR101593A2 (es) Formulación superfina de formoterol
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
TN2009000504A1 (en) Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
WO2007020204A3 (en) Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate
MX2014004364A (es) Composiciones que comprenden sulfato de salbutamol.
SG149054A1 (en) Multiparticulate formulations for oral delivery
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
WO2013104892A8 (en) Application of high dose compounds via inhalation
WO2008106689A3 (en) Breakthrough pain management
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
BRPI0607990A2 (pt) formulação de um aerossol farmacêutico para inaladores dosimetrados pressurizados contendo um agente seqüestrante, uso do agente sequestrante, inalador de dosimetrado pressurizado e método de preenchimento do inalador de aerossol
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
WO2008079343A3 (en) Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
SE0401612L (sv) Inhalator som använder balja
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
JO3024B1 (ar) صيغ أيروسول صيدلانية من الفرموتيرول وبكلوميتازون داي بروبيونات
CR9941A (es) Formacion farmaceutica de absorcion oral y su metodo de administracion